AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$SOPH

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 10:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 10:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$SOPHBullishMed
01

Why it matters

The earnings call provides fresh guidance and profitability targets, offering traders a clear catalyst for price movement.

02

Market read

First‑report earnings guidance for SOPHiA, indicating higher revenue and a path to EBITDA breakeven, likely to move the stock.

03

What to watch

Potential headwinds from foreign‑exchange weakness and competitive pressure from Guardant Health.

Relevance 7/10Novelty 7/10Timing: post-earnings today

Background

SOPHiA GENETICS reported strong U.S. revenue growth, expanding liquid biopsy volume, and a legal win against Guardant Health.

Company-level read

Ticker impact

$SOPHBullishHigh confidence
Context

Q3 2026 earnings call disclosed full-year 2026 revenue guidance of $94M-$96M and a path to positive adjusted EBITDA in H2 2027.

Expected impact

likely upside as investors price in stronger revenue outlook and EBITDA breakeven path

Evidence & confidence

Guidance is primary disclosure with material numbers for a listed company; market typically reacts positively to better-than-expected revenue and clear profitability trajectory.

Market effects

Sector

Strengthens outlook for genomic sequencing and AI‑driven diagnostics sector.

Regional

Positive for Swiss biotech and U.S. health‑tech investors.

Global

Highlights growing demand for decentralized genomic testing worldwide.

Counterpoint

What could challenge this read

Guidance may be optimistic; execution risk on cost discipline and market adoption could limit upside.

Key entities

  • company
    SOPHiA GENETICS S.A.

    Swiss genomics and AI diagnostics firm listed on Nasdaq (SOPH).

  • company
    Guardant Health

    Competitor involved in a legal dispute resolved in SOPHiA's favor.

Read at source← All news

Also covered by

1 outlet

Related articles

NOV 4
$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

finance.yahoo.com7 min
NOV 3
$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

finance.yahoo.com3 min
NOV 3
$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

finance.yahoo.com6 min
NOV 3
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September

SEC EDGAR 6-K3 min
AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min